vimarsana.com

Page 2 - பல்கலைக்கழகம் ஆஃப் டோக்கியோ விளிம்பு மூலதனம் கூட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Japan s UTEC secures first close of fifth global deep tech fund at $275m

streetAsia s premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. SUBSCRIBE NOW Singapore Reporter/s In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digi

Big Money for Gene Editing, Engineering, Structure-Based Drug Design, and Data Management

April 29, 2021 April 29, 2021 | Illumina joins the Gates Foundation in a global pathogen genomics initiative, new money for immune profiling, and Benchling nets $200M for their cloud platform.   $375M: Fund for Growth-Stage Medtech, Digital Health  Endeavour Vision has closed Endeavour Medtech Growth II (EMG II) LP at USD 375 million in capital commitments. The fund will pursue the same strategy as its predecessor: to support growth-stage medtech and digital health innovations that advance the standard of care and bring efficiencies to healthcare systems. Both new and returning investors supported EMG II LP, including public pension funds, multi-manager funds, family offices, and high-net-worth individuals. EMG II LP builds on Endeavour Vision’s two decades of healthcare investing, which to date has included over USD 500 million invested in 42 companies 21 of which have exited via an acquisition or IPO. The fund has already supported seven companies with investm

Singaporean startup ImmunoScape raises $14M to advance capabilities

Singaporean startup ImmunoScape raises $14M to advance capabilities Singaporean startup ImmunoScape raises $14M to advance capabilities 19 April 2021 | News Round is co-led by EDBI, Anzu Partners and UTEC, representing major biotech innovation centers across the U.S., Singapore and Japan Image credit- shutterstock.com ImmunoScape, a Singapore headquartered biotech company with an immunomics-based technology platform that provides novel insights into the human immune system, has announced it has completed a $14 million fundraising round led by existing investors Anzu Partners, University of Tokyo Edge Capital Partners (UTEC) and new investor EDBI, an investment arm of the Economic Development Board of Singapore. The new round brings ImmunoScape’s total funding in the past year to $25 million.

Fresh $18m fund injection for Singapore biotech firm doing Covid-19 research

Fresh $18m fund injection for Singapore biotech firm doing Covid-19 research
straitstimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from straitstimes.com Daily Mail and Mail on Sunday newspapers.

ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery

ImmunoScape Raises $14M To Advance Deep Immunomics Platform for High-Dimensional Immune Profiling and Drug Discovery
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.